组织蛋白酶 D(CatD)是由CTSD 基因编码的溶酶体天冬氨酸蛋白酶,可在酸性环境下水解蛋白质,并通过蛋白剪切激活生物活性前体物质。其分子结构包含信号肽、前肽及催化结构域,催化结构域内两个天冬氨酸残基是维持酶活性的核心位点。
在激素依赖性乳腺癌中,雌激素受体(ER)信号通路可通过上游刺激因子 USF-1、USF-2 结合 E 盒元件,依托 TATA 依赖型转录起始机制,上调组织蛋白酶 D 的表达。在雌激素受体阳性肿瘤中,分泌型组织蛋白酶 D 可降解细胞外基质、增强细胞运动能力,进而促进肿瘤转移。临床研究证实,组织蛋白酶 D 的表达水平与乳腺癌高组织学分级等恶性表型密切相关,同时提示患者生存期缩短。
在阿尔茨海默病(AD)病理进程中,组织蛋白酶 D 与 β 淀粉样蛋白(Aβ)斑块、神经原纤维缠结存在共定位现象;生理状态下该酶可降解 Aβ42 与 tau 蛋白。但 Aβ42 大量蓄积会竞争性抑制组织蛋白酶 D 活性,阻碍 tau 蛋白清除,最终加剧神经退行性病变。
香烟烟雾可提升肺泡巨噬细胞及支气管肺泡灌洗液中组织蛋白酶 D 的活性,通过破坏肺部基质结构诱发肺气肿。
在临床诊疗领域,组织蛋白酶 D 可作为乳腺癌预后分层标志物,同时用于预判他莫昔芬药物耐药性。以胃酶抑素 A 及靶向活性位点的小分子衍生物为代表的组织蛋白酶 D 抑制剂,目前正用于转移性乳腺癌与阿尔茨海默病的相关研究。对于吸烟人群,检测支气管肺泡灌洗液中组织蛋白酶 D 含量(>3600 U/mL)可早期筛查肺损伤,指导预防性干预措施。组织蛋白酶 D 在机体蛋白稳态调控与多种疾病进程中发挥双重作用,具备成为多功能治疗靶点的巨大潜力。
蛋白含量测定:消光系数\(E=1.00\)(质量分数 0.1% 溶液,280 nm 波长,1 cm 光程)
Cathepsin D (CatD), a lysosomal aspartyl protease encoded by the CTSD gene, functions in protein degradation and activation of bioactive precursors through cleavage at acidic pH. Its structure includes a signal peptide, propeptide, and catalytic domain with two aspartic residues essential for enzymatic activity. Estrogen receptor (ER) signaling drives CatD overexpression in hormone-responsive breast cancers via TATA-dependent transcription initiation, mediated by upstream stimulatory factors USF-1/USF-2 binding to E-box elements. In ER-positive tumors, CatD secretion promotes metastasis by degrading extracellular matrix components and enhancing cell motility. Clinically, CatD expression correlates with aggressive breast cancer phenotypes, including high histological grade, and reduced survival.
In Alzheimer’s disease (AD), CatD colocalizes with amyloid-β (Aβ) plaques and neurofibrillary tangles, where it degrades both Aβ42 and tau under normal conditions. However, Aβ42 accumulation competitively inhibits CatD, impairing tau clearance and exacerbating neurodegeneration. Cigarette smoke elevates CatD activity in alveolar macrophages and bronchoalveolar lavage fluid, contributing to emphysema via lung matrix degradation.
Therapeutically, CatD serves as a prognostic biomarker for breast cancer stratification and a predictor of tamoxifen resistance. Inhibitors like pepstatin A and small-molecule analogs targeting its active site are under investigation for metastatic breast cancer and AD3. In smokers, monitoring BALF CatD levels (>3,600 U/mL) may identify early lung damage, guiding preventive interventions. These dual roles in proteostasis and disease underscore CatD’s potential as a multifunctional therapeutic node.
Protein Determination: Extinction Coefficient (E) = 1.00 (0.1% at 280 nm, 1 cm pathway)
Prepared from tissue collected in the contiguous 48 United States from animals under 30 months of age at a USDA-inspected facility. Animals were inspected ante mortem and found free from obvious signs of infectious and contagious diseases.